The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma

Neuroblastomas (NBs) harboring activating point mutations in Anaplastic Lymphoma Kinase (ALK) are differentially sensitive to the ALK inhibitor crizotinib, with certain mutations conferring intrinsic crizotinib resistance. To overcome this clinical obstacle, our goal was to identify inhibitors with...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Discov
Main Authors: Infarinato, Nicole R., Park, Jin H., Krytska, Kateryna, Ryles, Hannah T., Sano, Renata, Szigety, Katherine M., Li, Yimei, Zou, Helen Y., Lee, Nathan V., Smeal, Tod, Lemmon, Mark A., Mossé, Yael P.
Format: Artigo
Jezik:Inglês
Izdano: 2015
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4707106/
https://ncbi.nlm.nih.gov/pubmed/26554404
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-15-1056
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki